Last reviewed · How we verify
Madopar® 250
Madopar® 250 is a Small molecule drug developed by Bial - Portela C S.A.. It is currently in Phase 1 development. Also known as: Levodopa/benserazide.
At a glance
| Generic name | Madopar® 250 |
|---|---|
| Also known as | Levodopa/benserazide |
| Sponsor | Bial - Portela C S.A. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg (PHASE1)
- Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Madopar® 250 CI brief — competitive landscape report
- Madopar® 250 updates RSS · CI watch RSS
- Bial - Portela C S.A. portfolio CI
Frequently asked questions about Madopar® 250
What is Madopar® 250?
Madopar® 250 is a Small molecule drug developed by Bial - Portela C S.A..
Who makes Madopar® 250?
Madopar® 250 is developed by Bial - Portela C S.A. (see full Bial - Portela C S.A. pipeline at /company/bial-portela-c-s-a).
Is Madopar® 250 also known as anything else?
Madopar® 250 is also known as Levodopa/benserazide.
What development phase is Madopar® 250 in?
Madopar® 250 is in Phase 1.
Related
- Manufacturer: Bial - Portela C S.A. — full pipeline
- Also known as: Levodopa/benserazide
- Compare: Madopar® 250 vs similar drugs
- Pricing: Madopar® 250 cost, discount & access